---
figid: PMC4810382__jpm-06-00003-g002
figlink: /pmc/articles/PMC4810382/figure/jpm-06-00003-f002/
number: F2
caption: Overview of the EGFR- and ALK-signaling pathways and their respective inhibitors.
  Ligand binding to EGFR leads to dimerization of the receptor, resulting in phosphorylation
  of the tyrosine kinase domain and activation of the PIK3/AKT/mTOR or the RAS/RAF/MEK/ERK
  signaling pathway. This signal transduction cascade could also be activated via
  EML4-Alk which, in turn, may initiate the JAK/STAT pathway. The affected pathways
  control cell growth and play a role in cell differentiation.
pmcid: PMC4810382
papertitle: 'Molecular Pathology and Personalized Medicine: The Dawn of a New Era
  in Companion Diagnostics—Practical Considerations about Companion Diagnostics for
  Non-Small-Cell-Lung-Cancer.'
reftext: Till Plönes, et al. J Pers Med. 2016 Mar;6(1):3.
pmc_ranked_result_index: '75093'
pathway_score: 0.9596038
filename: jpm-06-00003-g002.jpg
figtitle: EGFR- and ALK-signaling pathways and their respective inhibitors
year: '2016'
organisms: Homo sapiens
ndex: b1b6d7bd-deb8-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4810382__jpm-06-00003-g002.html
  '@type': Dataset
  description: Overview of the EGFR- and ALK-signaling pathways and their respective
    inhibitors. Ligand binding to EGFR leads to dimerization of the receptor, resulting
    in phosphorylation of the tyrosine kinase domain and activation of the PIK3/AKT/mTOR
    or the RAS/RAF/MEK/ERK signaling pathway. This signal transduction cascade could
    also be activated via EML4-Alk which, in turn, may initiate the JAK/STAT pathway.
    The affected pathways control cell growth and play a role in cell differentiation.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT2
  - ALK
  - AKT1
  - STAT2
  - STAT3
  - RAF1
  - AKT3
  - MAPK1
  - BRAF
  - EGFR
  - EML4
  - JAK3
  - MAPK3
  - JAK1
  - JAK2
  - KRAS
  - MAP2K2
  - MTOR
  - ARAF
  - STAT6
  - NRAS
  - STAT5A
  - HRAS
  - STAT5B
  - STAT4
  - TYK2
  - STAT1
  - MAP2K1
  - LY294002
  - PD184352
  - Tipifarnib
  - Canertinib
  - Neratinib
  - Selumetinib
  - Trametinib
  - Dabrafenib
  - Rapamycin
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: ALK
  symbol: ALK
  source: hgnc_symbol
  hgnc_symbol: ALK
  entrez: '238'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT2
  entrez: '6773'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: EML4
  symbol: EML4
  source: hgnc_symbol
  hgnc_symbol: EML4
  entrez: '27436'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK3
  entrez: '3718'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT6
  entrez: '6778'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT5A
  entrez: '6776'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT5B
  entrez: '6777'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT4
  entrez: '6775'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: TYK2
  entrez: '7297'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT1
  entrez: '6772'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
chemicals:
- word: LY294002
  source: MESH
  identifier: C085911
- word: PD184352
  source: MESH
  identifier: C120227
- word: Tipifarnib
  source: MESH
  identifier: C402769
- word: Canertinib
  source: MESH
  identifier: C420268
- word: Neratinib
  source: MESH
  identifier: C487932
- word: Selumetinib
  source: MESH
  identifier: C517975
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Dabrafenib
  source: MESH
  identifier: C561627
- word: Rapamycin
  source: MESH
  identifier: D020123
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC4810382__F2
redirect_from: /figures/PMC4810382__F2
figtype: Figure
---
